KEYNOTE-059 demonstrated that patients with PD-L1-positive gastric cancer (CPS >  = 1) had a longer median duration of response and a higher objective response rate, which led to the FDA authorizing pembrolizumab as a third-line therapy for patients with PD-L1-positive (CPS >  = 1) gastric cancer (Fuchs et al. 2018). This evidence concerns the gene CD274 and gastric cancer.